Cargando…

Safety and Effectiveness of Reduced Dose Versus Standard Dose Enoxaparin Venous Thromboembolism Prophylaxis in Underweight Medically Ill Patients

Background: Enoxaparin is commonly used for venous thromboembolism (VTE) prophylaxis in hospitalized patients. Published literature exists for dose adjustment in higher body weights and renal dysfunction, but sparse literature on optimal dosing of prophylactic enoxaparin in underweight patients exis...

Descripción completa

Detalles Bibliográficos
Autores principales:	Nemeth, Abigail, Isherwood, Manuel
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2022
Materias:	Original Research Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9986578/ https://www.ncbi.nlm.nih.gov/pubmed/36890953 http://dx.doi.org/10.1177/00185787221123220

Ejemplares similares

Enoxaparin Dosing for Venous Thromboembolism Prophylaxis in Low Body Weight Patients
por: Dybdahl, Daniel, et al.
Publicado: (2019)

Optimal Dosing of Enoxaparin in Critically Ill Patients with Venous Thromboembolism
por: Abdulla, Aliya, et al.
Publicado: (2023)

Safety of Enoxaparin as Venous Thromboembolism Prophylaxis After Rhytidectomy
por: Lisiecki, Jeffrey L., et al.
Publicado: (2019)

Venous Thromboembolism Prophylaxis in Underweight Hospitalized Patients
por: Buckheit, Douglas, et al.
Publicado: (2021)

The Pattern of Heparin Dosing as Venous Thromboembolism Prophylaxis in Adult Underweight Patients Admitted to Critical Care Units at a Tertiary Hospital
por: Al Harthy, Nouf, et al.
Publicado: (2022)

Reduced dosing of enoxaparin for venous thromboembolism in overweight and obese adolescents: a single institution retrospective review
por: Hoffman, Stephanie, et al.
Publicado: (2017)

The use of enoxaparin as venous thromboembolism prophylaxis in bariatric surgery: A retrospective cohort study
por: Altawil, Esraa, et al.
Publicado: (2022)

742 Evaluation of Anti-Xa Levels and Venous Thromboembolism Prophylaxis with Enoxaparin in Burn Patients
por: Boyd, Allison, et al.
Publicado: (2023)

Ethical Concerns Regarding High-Dose Enoxaparin for Venous Thromboembolism Prevention in Plastic Surgery Patients
por: Swanson, Eric
Publicado: (2019)

Enoxaparin versus dalteparin or tinzaparin in patients with cancer and venous thromboembolism: The RIETECAT study
por: Trujillo‐Santos, Javier, et al.
Publicado: (2022)

Prevention of venous thromboembolism with enoxaparin in bariatirc surgery
por: Woo, Hee Doo, et al.
Publicado: (2013)

Utility of D-dimers and intermediate-dose prophylaxis for venous thromboembolism in critically ill patients with COVID-19
por: Zermatten, Maxime G., et al.
Publicado: (2020)

Assessment of anti-factor Xa activity of enoxaparin for venous thromboembolism prophylaxis in morbidly obese surgical patients
por: Al Otaib, Nouf, et al.
Publicado: (2017)

Value of venous thromboembolism prophylaxis by enoxaparin with anti-factor Xa trough concentration monitoring in surgical care
por: Zachariah, Seeba, et al.
Publicado: (2020)

Prophylaxis and treatment of venous thromboembolism in the critically ill
por: Adriance, Sarah M, et al.
Publicado: (2013)

Standard- versus intermediate-dose enoxaparin for anti-factor Xa guided thromboprophylaxis in critically ill patients with COVID-19
por: Hamilton, David Oliver, et al.
Publicado: (2021)

Once-daily vs. twice-daily dosing of enoxaparin for the management of venous thromboembolism: A systematic review and meta-analysis
por: Niu, Jingrong, et al.
Publicado: (2020)

Bemiparin versus Enoxaparin in the Prevention of Venous Thromboembolism among Intensive Care Unit Patients
por: Abbas, Mohamed Sayed
Publicado: (2017)

Efficacy and Safety of Enoxaparin for Preventing Venous Thromboembolic Events following Urologic Laparoscopic Surgery
por: Nomura, Takeo, et al.
Publicado: (2013)

Efficacy and safety of enoxaparin as deep vein thrombosis prophylaxis in critically ill patients
por: Al-Hubail, R, et al.
Publicado: (2012)

Study on the safety and effectiveness of low-dose vs. regular-dose fondaparinux in preventing venous thromboembolism prophylaxis following total knee arthroplasty
por: Chen, Ping-bo, et al.
Publicado: (2023)

Efficacy and safety of edoxaban versus enoxaparin for the prevention of venous thromboembolism following total hip arthroplasty: STARS J-V
por: Fuji, Takeshi, et al.
Publicado: (2015)

Comparison of Enoxaparin and Rivaroxaban in the Prophylaxis of Deep Venous Thrombosis in Arthroplasty
por: Çiçek, Necati, et al.
Publicado: (2021)

Direct Oral Anticoagulants Vs. Enoxaparin for Prevention of Venous Thromboembolism Following Orthopedic Surgery: A Dose–Response Meta‐analysis
por: Boyd, RA, et al.
Publicado: (2017)

Rivaroxaban versus enoxaparin/vitamin K antagonist therapy in patients with venous thromboembolism and renal impairment
por: Bauersachs, Rupert M, et al.
Publicado: (2014)

Rivaroxaban versus enoxaparin for the prevention of recurrent venous thromboembolism in patients with cancer: A meta-analysis
por: Xing, Jiali, et al.
Publicado: (2018)

Comparison between standard Vs. Escalated dose venous thromboembolism (VTE) prophylaxis in critically ill patients with COVID-19: A two centers, observational study
por: Aljuhani, Ohoud, et al.
Publicado: (2022)

Rivaroxaban Versus Enoxaparin for Thromboprophylaxis After major Gynecological Cancer Surgery: The VALERIA Trial: Venous thromboembolism prophylAxis after gynecoLogical pElvic cancer surgery with RIvaroxaban versus enoxAparin (VALERIA trial)
por: Longo de Oliveira, André Luiz Malavasi, et al.
Publicado: (2022)

Standard dosing of enoxaparin versus unfractionated heparin in critically ill patient with COVID-19: a multicenter propensity-score matched study
por: Al Sulaiman, Khalid, et al.
Publicado: (2022)

Pharmacological prophylaxis for venous thromboembolism: Is it time to change the gold standard?
por: Kumaraswamy, Santosh
Publicado: (2021)

Safety of heparin prophylaxis for venous thromboembolism in patients with neurotrauma
por: Puri, G, et al.
Publicado: (2010)

Safety of apixaban for venous thromboembolism prophylaxis: the evidence to date
por: Trkulja, Vladimir
Publicado: (2016)

The economic impact of enoxaparin versus unfractionated heparin for prevention of venous thromboembolism in acute ischemic stroke patients
por: Pineo, Graham F, et al.
Publicado: (2012)

Rivaroxaban versus enoxaparin for the prevention of venous thromboembolism after total knee arthroplasty: A meta-analysis
por: Huang, Hai-Feng, et al.
Publicado: (2018)

Cost-Effectiveness Rivaroxaban versus Enoxaparin for Prevention of Venous Thromboembolism after Knee Replacement Surgery in Iran
por: Abutorabi, Ali, et al.
Publicado: (2023)

Intermittent pneumatic compression versus additional prophylaxis with enoxaparin for prevention of venous thromboembolism after laparoscopic surgery for gastric and colorectal malignancies: multicentre randomized clinical trial
por: Kamachi, H., et al.
Publicado: (2020)

Patterns of Non-Administration of Ordered Doses of Venous Thromboembolism Prophylaxis: Implications for Novel Intervention Strategies
por: Shermock, Kenneth M., et al.
Publicado: (2013)

Comparison of Fatal or Irreversible Events With Extended‐Duration Betrixaban Versus Standard Dose Enoxaparin in Acutely Ill Medical Patients: An APEX Trial Substudy
por: Gibson, C. Michael, et al.
Publicado: (2017)

Venous thromboembolism prophylaxis on flights
por: Marques, Marcos Arêas, et al.
Publicado: (2018)

Case report – Gluteal hematoma in two spinal cord patients on enoxaparin for venous thromboembolism prophylaxis: evidence needed for a wiser choice
por: de Almeida, Rodrigo Lanna, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_tkfc6lvd1eictt18sgielj3s6m